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Abstract
Counterfeit medicines potentially reach 70% of the global drug markets, and the largest proportion is found in developing countries. Increasing public aware-
ness of counterfeit medicines will automatically affect the demand for counterfeit medical products that will finally reduce counterfeit medicine activities.
However, raising awareness of the dangers of counterfeit medicines is a challenging task because public health professionals need to consider diversity of
social, economic and educational factors. This study examined peer-reviewed journal articles, media reports, official government and non-government reports.
As many as 179 papers (1990 to 2014) were retrieved to identify the relationship between Human Development Index (HDI) of the USA, Japan, Brazil, Iran,
Vietnam, Indonesia, Pakistan and Nigeria, and the type of counterfeit medicines. An electronic search was conducted using the following databases, such as
Medline, Scopus, CINAHL, Embase, Google Scholar. Counterfeit disease curing medicines are found in high varieties most likely in countries with low HDI.
At the same time, medicines for lifestyle are not solely found in countries with high HDI, but also exist in low to medium HDI.
Keywords: Counterfeit medicines, disease curing medicine, human development index, lifestyle of drug use, public health
Abstrak
Obat-obatan palsu berpotensi mencapai 70% dari pasaran obat internasional dengan proporsi terbanyak ditemukan di negara berkembang. Meningkatkan
kesadaran masyarakat akan adanya obat-obatan palsu akan secara langsung memengaruhi permintaan produk obat palsu yang akhirnya akan mengurangi
kegiatan pemalsuan obat. Akan tetapi, meningkatkan pengetahuan masyarakat akan bahaya obat-obatan palsu tidaklah mudah sebab profesi kesehatan
masyarakat harus juga mempertimbangkan keberagaman faktor-faktor sosial, ekonomi dan pendidikan. Laporan ini menelaah artikel jurnal yang ditelaah oleh
kelompok seminat, laporan media, laporan resmi pemerintah dan non-pemerintah. Sebanyak 179 artikel (dari 1990 sampai 2014) ditelaah untuk mengetahui
hubungan antara indeks pembangunan manusia (IPM) dari USA, Jepang, Brasil, Iran, Vietnam, Indonesia, Pakistan dan Nigeria, dan tipe pemalsuan obat.
Pencarian elektronik menggunakan pangkalan data seperti Medline, Scopus, CINAHL, Embase, Google Scholar. Obat-obatan palsu untuk pengobatan dite-
mukan dalam banyak ragam terutama di negara dengan IPM rendah. Pada saat yang sama, obat-obatan untuk keperluan gaya hidup tidak hanya ditemukan
di negara dengan IPM tinggi, akan tetapi juga beredar di negara dengan IPM rendah dan sedang.  
Kata kunci: Obat palsu, pengobatan penyakit, indeks pembangunan manusia, gaya hidup penggunaan obat, kesehatan masyarakat
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Introduction
Counterfeit medicine is on the rise globally and an
emerging issue in both developing and developed coun-
tries. However, the true extent of the problem is not re-
ally known because no global study has been conducted.1
The World Health Organization (WHO) estimates that
6% of worldwide pharmaceutical sales are counterfeit
and that up to 70% of all medicines sold in several de-
veloping countries are counterfeit.1 The government au-
thorities and medicine manufacturers have made exten-
sive attempts to fight drug counterfeiting, but old and
new counterfeiters have used several methods to escape
detection.2
Many types of medicines have been counterfeited, in-
cluding antibiotics, hormones, analgesics, steroids, anti-
histamines, vitamins, malaria medicines, flu medicines,
and HIV/AIDS medicines.3,4 However, the exact amount
of counterfeit medicine is unknown, and little reliable da-
ta are available for both developed and developing coun-
tries. In some developing countries, the problem of data
gathering is made more difficult due to a lack of agree-
ment on the definition of counterfeit medicine and these
countries are often reluctant to make information on
counterfeit medicine public.3,5
Countries with low socioeconomic factor are more
vulnerable to widespread counterfeit medicines due to
the high price of the medications.6 People in developing
countries must choose between low price counterfeit
medicines or not buying any medicine. Drugs that are
frequently counterfeited in developing countries are med-
icines that are used to treat life-threatening diseases, such
as malaria, tuberculosis, HIV/AIDS, and other serious in-
fectious conditions.7 In contrary, counterfeit lifestyle
medicines are most likely to be found in developed coun-
tries.8,9 In developed countries, counterfeiters aim for
high demand or costly products, such as medicines used
to treat erectile dysfunction, hypercholesterolemia, hy-
pertension and cancer.10,11 Thus, it is unclear whether
counterfeit medicine is prevalent in the countries that
have a low per capita income and low education level, or
if counterfeit medicines are increasing in developed coun-
tries because counterfeiters target high demand and re-
sale value. 
To address the counterfeit medicine problem, WHO
has developed a definition that a counterfeit medicine is
a medicine which is fraudulently and deliberately misla-
beled with respect to identity and/or source.
Counterfeiting can apply to both branded and generic
products, and counterfeit products may include products
with the correct ingredients or with the wrong ingredi-
ents, without active ingredients, with insufficient active
ingredients or with fake packaging.1,12 Every medicine
counterfeiting activity has significant repercussions for
society, potentially threatening public health because con-
sumption of counterfeit medicines may lead to death or
ineffective treatment.
According to Spink,13 and Moyer,14 from Michigan
State University, there are seven types of fraud and coun-
terfeiting incidents and their potential harm to public
health. The first type is adulteration, in which the coun-
terfeiter adds more ingredients with the intention of for-
ging components of the products. The result is a product
that is impure, that has lost the active ingredient, or that
is given at an improper dose. The second type is tampe-
ring, in which the counterfeiter obtains the original pro-
duct and packaging, but with the intent to fraudulently
use them. For example, the counterfeiter may change the
expiration date or product labelling. This may lead to the
death of the consumer. The third type is overrun, in
which the counterfeiter outside of the quantity makes le-
gitimate medicines in a production agreement. These ac-
tivities are dangerous because the product will be dis-
tributed outside the regulated or controlled supply chain.
The fourth type is theft, in which the counterfeiter steals
legitimate products and sells them as legitimate pro-
ducts. Similar to overrun, legitimate products will be dis-
tributed outside the regulated or controlled supply chain.
The fifth type is diversion, which is also known as a pa-
rallel trade, the grey market or product arbitrage. This
type of fraud may result in a lack of legitimate products
in the market, causing a delay in a patient getting the
medicine. Another type is simulation, in which the coun-
terfeiter copies the legitimate product but does not use
the same ingredients. This will affect patient safety, as
the resulting medicine is fake or of a lower quality. The
last type is counterfeiting, where the counterfeiter copies
exactly the same drug as the legitimate product with the
intention to mislead the patient. The product and pack-
aging of the legal medicines are fully replicated, which
causes the patient to consume a product that is evident-
ly impure.
Combating counterfeiting/fraud activities requires a
strong commitment from the governments and authori-
ties around the world.15 Knowledge of the reasons why
counterfeiters falsify medicines is also very important.
The medicine product supply chain is controlled by the
government under the law; however, people can help to
decrease the demand for counterfeit medicines by pur-
chasing medicines from authorised pharmacies.16
Economic factors are one of main reasons for coun-
terfeiting medicines. However, other motivations also ex-
ist, such as part of terrorist activities or for other crimi-
nal motives.15,17 Socioeconomic factors contribute to
counterfeiting activities in many countries. A prior study
has investigated aspects of the relationship between so-
cioeconomic variables and counterfeit medicine.18
However, indicators of socioeconomic status, such as ed-
ucation, income, and culture are independent variables.
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For example, people that have the same level of formal
education could have different perspectives on health due
to different cultural backgrounds.19,20 These perspec-
tives at times lead to incorrect conclusions about the re-
lationship between socioeconomic indicators and health
outcomes or health perspectives in general. The aim of
this study was to determine whether or not the type of
medicines (medicine for lifestyle or disease treatment)
related to the socioeconomic factors based on the human
development index (HDI) in eight selected countries of
the world. 
Method
Identification of Studies
This search strategy and term were utilised a system-
atic review style an approach which is considered a legi-
timate study methodology.21 To identify and highlight the
primary study studies and to determine the relationship
between HDI and type of medicines being counterfeited
in Eight selected countries, four major electronic data-
bases such as Medline, Scopus, CINAHL, EMBASE,
Google Scholars were used. The keywords included
‘counterfeiting’, ‘counterfeit medicines’, ‘substandard
drugs’, ‘fake drugs’, ‘world counterfeiting’, and ‘counter-
feit medicines’ as well as ‘counterfeit drugs/medi-
cines/medicines’ in eight selected countries that are the
USA, Japan, Brazil, Iran, Indonesia, Vietnam, Nigeria and
Pakistan. Extracted data about counterfeit medicines
were analyzed using a table that categorized counterfeit
medicines based on their labelling package type medi-
cines. The medicines were then grouped into two broad
classes, namely lifestyle drugs and disease curing me-
dicine classes. 
Inclusion Criteria
Records that reported on the prevalence and potential
public health and socioeconomic concern of counterfeit
medicines in developed and developing countries were
selected using preferred reporting items for systematic
reviews and Meta-Analysis (PRISMA) guideline proce-
dure (Figure 1). The title and abstracts of the identified
articles were checked against predetermined criteria for
eligibility of the study that deal with various aspects of
counterfeit medicines for lifestyle and disease treatment
and relevant to the study objectives. The most informa-
tive version of the study was included in multiple publi-
cation that presented identical data. A study published in
Indonesian language was then translated, and relevant
papers were included. The full text of all selected studies
was obtained and assessed. Of 179 potential articles
identified by these criteria, 58 studies were included for
eligibility. Lastly, remaining ten records was included in
the narrative synthesis. The selected countries were se-
lected based on the HDI with very high HDI in USA and
Japan, high HDI in Brazil and Iran, medium HDI in
Indonesia and Vietnam, and low HDI in Nigeria and
Figure 1. PRISMA Flow Diagram Showing the Exclusion and Inclusion of Studies for Analysis
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Pakistan.22
Exclusion Criteria
At first, a total of 179 articles were identified through
searching various database (153 articles) and other
sources (26 articles). However, 53 articles were rejected
because of repetition and resultant 126 articles were cho-
sen. In the screening phase, 68 studies were excluded as
they reported in language other than English and
Indonesian, and did not report outcomes of interest.
Subsequently, in the eligibility phase, 48 articles were
eliminated as they were not included into cases in eight
selected countries (USA, Japan, Brazil, Iran, Indonesia,
Vietnam, Pakistan, Nigeria).
Results
A review of the 153 published and 26 additional
records between 1990 to 2014 was conducted on the type
of counterfeit medicines in relation with socioeconomic
factors based on eight selected HDI countries. The review
of the literature included peer-reviewed journal articles,
media reports, government and non-government reports.
Table 1. Units of Analysis from Peer-Reviewed Journals
Author Sampling Technique/Sample Purpose Study Design Findings
Beverly D Glass9 Not specified To review on counterfeit medicines Not specified Primarily expensive medicines for lifestyle such as
and medical devices in developing sildenafil and tadalafil are counterfeited in the 
countries. developed world, while those drugs frequent
ly counterfeited in developing countries are to 
treat life-threatening diseases such as malaria, 
tuberculosis, HIV/AIDS, and other serious 
infectious disease.
IMPACT,23 110 samples medicines from To investigate the medicine market Cross-sectional Counterfeit anti-malarial accounted 6 % of all 
6 countries (China, Indonesia, surveillance in the six participating study samples, erectile dysfunction medicines comprised 
Laos, Myanmar, Thailand, countries 16% of samples, antibiotic, antipsychotics an
Vietnam) tiplatelet made up 18% of the samples.
Vietnam: Vietnamese police were able to detect and
seize 8 cases of counterfeit medicines in 2008 com
prised of 14,000 Viagra tablets, 170 Cialis blister, 
1022 Augmentin, 75 Levista boxes, 106 Rovanten,
200 Vinka, 43 Amoxicillin. Both life-threatening 
and lifestyle medicines were found in China, 
Indonesia, Vietnam, Thailand, Laos and Myanmar.
Hosseini SA et al.24 Simple random sampling To gain insight into the medicine grey Cross-sectional Of the 716 bogus medicines: 64.5% were
(n=716) of counterfeit medicines market in Iran. Define the counterfeit retrospective supplement10.2% were analgesic, 7.8% were
medicine pattern in Iran study. hormones, 3.2% were antihistamines, 2-4% 
unknown, 1-2% cardiovascular disease medicine, 
diabetes medicines, genitourinary system, 
gastrointestinal system.
Ames J 25 Not mentioned To identify the main counterfeit seized Retrospective The medicine with greatest numbers of seizure 
by the Brazilian federal police and the descriptive study were selective phosphodiesterase five inhibitors  
states where seizure have been made. that are used for treatment male erectile 
dysfunction; Cialis, Viagra; mean =66%. Followed
by anabolic steroids (durateston and hemogenin) 
8.9% and 5.7 %.
JPMA26 n=88.543 To Understand the current activities Cross-sectional Most medicine counterfeit medicines were drugs 
number of seizures of imported concerning counterfeit medicines and internet survey to for the improvement of sexual performance.
IP infringing medicines cases the level of impact on member 53 member Total cases found in Japan domestic capital
seized companies  of the JPMA, and to companies of JPMA companies; Number of cases:
prepare plans for the further strategies Antibiotic (22), antiviral drugs (5), drugs for
combating counterfeited drugs improvement sexual performance (1,643), oral 
contraceptives (38), Alopecia drugs (6), anti-
obesity (2), anticancer (59), antipsychotic drugs 
(6), anti-depressant (4), Dementia drugs (6), 
anti-depressant (4), anti-hypertensives (14), lipid 
lowering drugs (22), external preparations (21), 
atopic dermatitis drugs (2), anti-diabetic drugs 
(59), anti-inflammatory analgesic (66), other (92).
Pfizer27 n=600.000 Sample of To remind of fake medicines which had Case study 18 million counterfeits Lipitor were seized.
counterfeited drugs spread to 15 US states Fake Lipitor was found in 15 USA states and
was suspected in a further six states.
Notes:
IMPACT = International Medical Product Anti-Counterfeiting Taskforce
JPMA = Japan Medicine Manufacturers Association
Kesmas: National Public Health Journal, 2017; 11 (4): 153-162
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There were 58 relevant peer-reviewed journal articles
identified, and six were based on five selected countries
setting (Table 1). Additionally, there were four reports
from government and media about counterfeit medicine
cases from three different selected countries (Table 2 and
Table 3).
The general outlook comparison between counterfeit
lifestyle medicines for and disease treatment in selected
countries based on HDI year 1990 to 2014 is presented
in Figure 2. From the graph, the number of counterfeit
lifestyle medicine is very high with 16 types in the very
high HDI countries followed by high and medium HDI
with nine types of counterfeit lifestyle, then low HDI
countries with medicines for five counterfeit lifestyle
medicines for.
On the other hand, the number of counterfeit medi-
cines for disease treatment in low HDI had the highest
types as many as fourteen, followed by medium HDI with
twelve types, then high HDI with nine types, and the last
was very high HDI with five types of counterfeit medi-
cines for treatment.
Discussion 
Measuring socioeconomic status in practice is not
simple. SES has many indicators that describe the indi-
vidual’s access to social and economic resources. Among
the most common, used indicators are education, occu-
pation, income, wealth, and years of school completed.36
The HDI was utilized in this study as it is the most
common value in representing the SES level in general.
The Human Development Index (HDI) reflects the posi-
tive association between income on one side and health
and education on the other. Thus, it offers a powerful al-
ternative to income as a summary measure of human
well-being.  
The food and drug administration (FDA) announced
the trafficking of fraudulent, counterfeit, and substan-
dard medicines, supplements, and medical devices from
several countries to the USA, including high demand
lifestyle medicines such as Botox and expensive medi-
cines such as cancer medicines.37
The FDA proactively responds to trafficking of coun-
terfeit medicines. Public awareness has increased sharply,
however, counterfeit medicines persist. If counterfeit
medicines can enter the legal supply chain in the USA,
the counterfeit medicine can most likely enter the mar-
kets of other countries.37
The cases of counterfeit medicines in selected coun-
tries with very HDI selected countries are higher than
others, more likely because of efficient counterfeiting cas-
es report file and well-organized anti-counterfeiting
agency.15
In countries with very high HDI, despite a well-pro-
tected supply chain, medicine quality control and good
social and physical security, counterfeit medicines still
can be found. People living in developed countries such
as Japan are exposed to fake medicines via illegal websites
in which unauthorized websites are difficult to monitor
and can easily escape the notice of authorities. Japan is a
country with a $96.5 billion expenditure in medicine, al-
most twice as much as Latin American medicine sales.38
in 2010, there were 490 cases of counterfeit medicine in
Japan, increasing approximately 7.3% from 2011.
Lifestyle medicines (Viagra and Cialis) were the major
medicine counterfeiting products.
This study found that most counterfeited medicines in
very high HDI were lifestyle medicines for. In developed
countries, counterfeiter generally targets high-volume,
high-cost drugs. This mean that the medicines potential-
ly targeted were lifestyle medicines. However, the data in
Table 2 also suggest that list has been expanded to near-
ly every kind of medicines, particularly those in high de-
mand like antiviral, anticancer medicines, etc.39
In 2012, the Brazilian authorities established 13-digit
Table 2. Units of Analysis from Official Website Drug Agencies, Media Report and Press Release on Counterfeit Medicines
Country Findings Website
USA28 Counterfeit medicines in the USA from 2002 to 2008; Diet pills, cancer medicines, U.S Food and Drug Administration.
growth medicines, male sexual enchanter, flu medicines, counterfeit medical 
devices, Botox.
Pakistan29-33 Counterfeit medicines found in Pakistan from 2002 to 2008; Fake herbal medicines, WHO, several media report and press release: the  
Dengue fever medicines, antibiotic, anti-tuberculosis medicines, anti-malarial news.com, samaa.tv, tribune.com, the nation.com, 
medicines, heart medicines, cancer medicines. safemedicines.org, radionz.
Vietnam34 Anti-malarial, antibiotic, anti-tuberculosis, antiretroviral medicines The State of Medicine Quality in the Mekong 
sub-region
Indonesia35 Total cases of counterfeit medicines from 2001 to 2008 in Indonesia were 162 cases. National Agency Drug and Food Control (BPOM)
Most counterfeit medicines were Antibiotic.
Total cases found: Antibiotic (39), antiviral drugs (7), drugs for improvement sexual 
performance (9), contraceptive (3), anti-obesity (2), anti-depressant (8), anti-
hypertensive (5), lipid lowering drugs (4), atopic dermatitis drugs (2), anti-diabetic 
drugs (13), vaccine (3), anti-allergy (14), drugs for improvement sexual 
performance (9), antifungal (11), others (7).
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unique drug identifiers for securing the medicine
products. Lifestyle medicines for are aimed at indications
where treatment is largely a matter of patient choice and
not a medical requirement. Patients consider embarrass-
ing products such as erectile dysfunction, obesity, and
those products are usually expensive as an apparent eco-
nomic incentive to counterfeiter.40
Unofficial and official reports about counterfeit -
Country Counterfeit Medicine- Type of Medicine Being 
Labelling Package Counterfeited
sgurd elytsefiLsllip teiDASU
Growth medicines Lifestyle medicines
Medicines for improvement of Lifestyle medicines
sexual performance
senicidem elytsefiLsenicidem ulF
senicidem elytsefiLxotoB
senicidem elytsefiLcitohcysp-itnA
Cancer medicines Disease curing medicines
Anabolic steroid Lifestyle medicines
Japan Medicines for the improvement of Lifestyle medicines
sexual performance
Oral contraceptive Lifestyle medicines
Anti-depressant Lifestyle medicines
Anti-psychotic Lifestyle medicines
Malaria medicines Disease curing medicines
Alopecia medicines Lifestyle medicines
senicidem elytsefiL ytisebo-itnA
Dementia medicines Lifestyle medicines
Lipid lowering medicines Disease curing medicines
Atopic dermatitis Lifestyle medicines
senicidem elytsefiLcitebaiditnA
Anti-inflammatory Disease curing medicines
senicidem gniruc esaesiDciseglanA
Brazil Medicines for improvement of Lifestyle medicines
sexual performance
Anabolic steroid Lifestyle medicines
senicidem elytsefiLevitpecartnoC
Cancer medicines Disease curing medicines
senicidem elytsefiLtnemelppuSnarI
senicidem gniruc esaesiDciseglanA
senicidem elytsefiLsenomroH
senicidem gniruc esaesiDenimatsih-itnA
Cardiovascular disease medicines Disease curing medicines
senicidem elytsefiL setebaiD-itnA
Genitourinary system medicines Disease curing medicines
Gastrointestinal system medicines Disease curing medicines
Eye & Eye Nose Throat Disease curing medicines
Musculoskeletal system Disease curing medicines
senicidem gniruc esaesiDenimatsih-itnA
Central Nervous system Disease curing medicines
senicidem elytsefiLslabreH
Dermatologists Lifestyle medicines
senicidem elytsefiLciportohcysP
Country Counterfeit Medicine- Type of Medicine Being
Labelling Package Counterfeited
senicidem elytsefiLsllip teiDaisenodnI
Anti-depressant Lifestyle medicines
Anti-inflammation Disease curing medicines
senicidem elytsefiLcitebaid-itnA
senicidem gniruc esaesiDignuf-itnA
Cough medicines Disease curing medicines
Lipid lowering medicines Lifestyle medicines
Anti-hypertension Disease curing medicines
Gastrointestinal medicines Disease curing medicines
medicines for the improvement of Lifestyle medicines
sexual performance
Malaria medicines Disease curing medicines
senicidem gniruc esaesiD ciseglanA
Cardiovascular medicines Disease curing medicines
senicidem elytsefiLnimatiV
Contraceptive oral Lifestyle medicines
Vietnam Medicines for the improvement of Lifestyle medicines
sexual performance
senicidem gniruc esaesiDcitoibitnA
senicidem elytsefiLsnimatiV
Malaria medicines Disease curing medicines
Anti-retroviral medicines Disease curing medicines
Anti-tuberculosis Disease curing medicines
Pakistan Dengue fever medicines Disease curing medicines
senicidem gniruc esaesiDcitoibitnA
Anti-tuberculosis drug Disease curing medicines
senicidem gniruc esaesiDlairalam-itnA
Disease curing medicines
Heart medicines Disease curing medicines
Cancer medicines Disease curing medicines
Medicines for the improvement of Lifestyle medicines
sexual performance
senicidem gniruc esaesiDciseglanAairegiN
senicidem elytsefiLcitebaid-itnA
Cancer medicines Disease curing medicines
Muscle relaxant Disease curing medicines
senicidem gniruc esaesiDcitpelipe-itnA
Immune thrombocytopenia Disease curing medicines
senicidem gniruc esaesiDcitoibitnA
senicidem gniruc esaesiDcitylocuM
senicidem elytsefiLsllip teiD
senicidem elytsefiLsnimatiV
Malaria medicines Disease curing medicines
Anti-anxiety medicines Lifestyle medicines
Table 3. Counterfeit Medicines in Eight Selected Countries Based on Types of Medicine Being Counterfeited
Figure 2. Comparison between Counterfeit Medicine for Lifestyle and Disease Treatment in Year
1990-2014 Selected Countries Based on HDI
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medicine have increased recently in Iran. From 2007 to
2008, there were 716 cases of counterfeit medicines, and
64.5% were potentially harmful supplements.24 Iran’s
geographical location is very important because of its
central location in Eurasia and Western Asia. However,
Iran’s political situation results in a breakdown of inter-
national trade.
In Vietnam, medicines for lifestyle such as sex en-
chantment medicines were most prevalent while coun-
terfeit antibiotic such as anti-malarial medicines were al-
so well-publicized cases.41 Indonesia and nine other
countries have participated in all five Operation Storm
campaigns as well as in Operation Pangea, which targets
online medicine sales. According to the National Agency
of Drug and Food Control of the Republic of Indonesia
(NADFC/Badan Pengawas Obat dan Makanan), 268,
219, 266, and 146 cases of counterfeit medicine were
found in 2003 to 2006, respectively.35 NADFC esta-
blished many ways to combat counterfeiters, including
encouraging the medicine industry to collaborate with
the government to eradicate counterfeit medicines, par-
ticipating in Operation Storm, and raising public aware-
ness of the dangers of counterfeit medicines. 
In low socioeconomic countries, it is often hard to
prove a causative link between counterfeit medicines and
illness or death because limited clinical autopsies and
toxicology report that explained the cause of death.42
There is one market where price is more important than
quality. The poorest consumers in Africa are forced to
choose between low-quality medicines that are inexpen-
sive or not purchasing the medicines at all. The ultimate
solution to this dilemma is for the government to ensure
that medicines for disease treatment are affordable for
all.7
The main factors underlying the problem of counter-
feit medicines in developing countries are the weak drug
regulatory control, enforcement, scarcity and/or erratic
supply of basic medicine, uncontrolled distribution
chains, large price differentials between genuine and
counterfeit medicines, lack of effective Intellectual
Property Right (IPR) protection, lack of regard for qua-
lity assurance and corruption of the health care system.43
Trends in counterfeit medicine vary depending on
many factors, such as the strength of the rule of law and
rural versus urban settings. These factors vary even with-
in countries. Health professionals play a major role in
helping medicines that reach patients without endanger-
ing patients’ health.44
In Nigeria, by 2001, more than 40% of medicines in
circulation were fake.45,46 Most counterfeit medicine
supplies (75%) were imported from China and India.4,47
People living in Nigeria are thus impacted by the danger-
ous effects of the counterfeit medicine. In 2008, 64% of
anti-malarial medicines were either counterfeit or sub-
standard.18 It is noted that low dose artesunate does not
kill malaria parasite but anchorages the emerge of arte-
sunate-resistant strains. 
Several counterfeit medicines seized in Nigeria are
heart medicines, cancer medicines, antibiotic, analgesic
and anti-malarial. These products include medicines for
lifestyleas well as for disease treatment. 
Similar to Nigeria, imports of counterfeit medicines in
Pakistan have also increased in recent years, along with
the increase of Pakistan’s local production and supply of
medicines. Meanwhile, the WHO estimated that as many
as 40 to 50% of needed medicines are substandard or
counterfeit medicine.33 Counterfeit medicines are ram-
pant in both rural and urban areas. Counterfeit versions
of life-saving prescription medicines for cancer and seri-
ous cardiovascular diseases were being sold to costumers
in Pakistan, meanwhile counterfeit antibiotic, analgesic
and antipyretic also well-noted. 43,44
In accordance with the law of supply and demand, as
the price of medicines rises, poor people will search for
medicines at low prices, and this leads to the vulnerabi-
lity of the people who are forced to choose to buy sub-
standard or counterfeit medicines from the illegal market.
Some illegal medicines in Iran are imported from India
and China. Most counterfeit medicines products seized
are supplements, hormone medicines, and analgesic and
antihistamine medicines. 24,48
Conclusion 
This review of articles shows that counterfeit medi-
cines are available in USA, Japan, Iran, Brazil, Indonesia,
Vietnam, Pakistan and Nigeria. Counterfeit medicines
can enter strong drug regulatory authorities such as in
USA and Japan as people living in these countries are
most likely exposed to counterfeit medicines via the in-
ternet. 
In very high and high development indexed countries,
expensive medicines for lifestyle (e.g. sildenafil, Cialis) as
well as expensive high demand medicines are counter-
feited. Meanwhile, in countries with medium and low de-
velopment index countries, medicines to treat life-threat-
ening diseases such as malaria, tuberculosis and other se-
rious conditions are counterfeited. Counterfeit medicines
pos a serious threat to the public health as medicine are
purposively to reduce mortality and morbidity, counter-
feit medicines are extremely harmful to health and safety
of patients. Furthermore, combating the counterfeit me-
dicines problem is important to ensure patients not to
lose faith in the benefits of medicines.
Recommendation
Counterfeit medicines pose an increase threat to peo-
ple as well as to individuals; direct harm to policy making
and social prosperity budget. People worldwide should
Nuryunarsih, Counterfeit Medicines in Socioeconomic Perspective
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understand about the harm of counterfeit medicines and
stop purchasing counterfeit medicines. The only way to
combat this lucrative fraudulent criminal is by decreasing
their sales. 
Improving quality of medicines, increase the avail-
ability of inexpensive essential medicines, as well as
strengthening medicine regulatory authority is a very im-
portant task for developing world to combat the coun-
terfeiter. 
At the national level, sustained political and economic
supports from the government to coordinate police, sci-
entist, medicine industries as well as enforcement the
laws and regulations on counterfeit medicines is crucial
to combat counterfeit medicines. 
Meanwhile, at the international level, drug registra-
tion should be strengthened to ensure that all imported
as well as local medicines industries produce high quali-
ty medicines before placing them to the market. To tack-
le the counterfeiter, there is also a need for continuous
cooperation between the government of developed and
developing countries and WHO.
Due to the expansion of the counterfeit medicines
through the internet, cooperation amongst policy ma-
kers, brand owners, entrepreneurs, marketers, and other
stakeholders is a key to controlling the availability and
supply of the counterfeit medicines from the internet.
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